EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy—Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method

H M Gunter, G Tatz, G Maartens, C W Spearman, U Mehta, K Cohen iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von H M Gunter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town,…. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Antitubercular Agents, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Academy of Medical Sciences, United Kingdom, Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We compared performance of the Roussel Uclaf Causality Assessment Method (RUCAM) with multidisciplinary expert panel review in identifying a drug‐induced liver injury (DILI) due to antituberculosis therapy (ATT) and/or antiretroviral therapy (ART).

Methods

Cases were drawn from a prospective registry of hospitalised adults with suspected DILI due to ATT and/or ART in Cape Town, South Africa. Participants had to fulfil American Thoracic Society criteria for ATT interruption (alanine transaminase [ALT] ≥5 times upper limit of normal [ULN]/ALT ≥3 times [ULN] and symptomatic). Causality assessment by expert panel review served as reference standard. The panel ranked potentially implicated drugs as certain, probable, possible or unlikely causes guided by World Health Organization Uppsala Monitoring Centre criteria. The RUCAM was performed for each potentially implicated drug. We calculated sensitivity and specificity of the RUCAM in identifying a probable/certain drug cause for liver injury.

Results

We included 48 participants. All were people with HIV (PWH). Twenty‐seven were on concomitant ART and ATT, with a median of six potentially hepatotoxic drugs per case. Sensitivity and specificity of the RUCAM in identifying a probable/certain drug cause of liver injury compared with expert panel review was 7% and 100% respectively. Implicated drugs (times ranked probable/certain by panel) were isoniazid (18/0), pyrazinamide (17/0), rifampicin (15/1), efavirenz (6/4) and lopinavir/ritonavir (1/0).

Conclusions

PWH with liver injury received multiple potentially implicated drugs, which may increase liver injury risk and complicate causality assessment. Compared with expert panel review, the RUCAM had low sensitivity in detecting probable or certain drug causes of liver injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryAntitubercular AgentsHIV InfectionsHumansAdultMaleFemaleSouth AfricaMiddle AgedProspective StudiesRegistriesAnti-HIV AgentsSensitivity and Specificity

Stichwörter der Autor:innen

RUCAMantiretroviral therapyantituberculosis therapycausality assessmentdrug‐induced liver injuryexpert panel review

Substanzen

Antitubercular AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: K Cohen

Förderung

  • Academy of Medical Sciences, United Kingdom
  • Academy of Medical Sciences

Zitieren

APA

Gunter, H. M., Tatz, G., Maartens, G., Spearman, C. W., Mehta, U., & Cohen, K. (2024). Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy—Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5883

Vancouver

Gunter HM, Tatz G, Maartens G, Spearman CW, Mehta U, Cohen K. Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy—Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5883

BibTeX
@article{Gunter2024,
  author = {Gunter, H M and Tatz, G and Maartens, G and Spearman, C W and Mehta, U and Cohen, K},
  title = {Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy—Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5883}
}
Kostenlos starten →